Open Nav

CohBar, Inc.

  • Simon Allen, COHBAR

Broader knowledge of the potential impact and value of CohBar's mitochondrial based therapeutics

  • Date:Thursday, October 18
  • Time:2:30 PM - 2:45 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:CohBar is a clinical stage biotechnology company whose mission is to increase healthy lifespan by developing treatments for the underlying metabolic dysfunction driving the diseases of aging including NASH, obesity, cancer, Type 2 diabetes, and cardiovascular and neurodegenerative diseases.
  • Company
  • Company HQ City:Menlo Park, CA
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Market Cap:$200M+
  • Ticker:CWBR
  • Exchange:NASDAQ
  • CEO/Top Company Official:Simon Allen
  • Year Founded:2009
  • Main Therapeutic Focus:Metabolic Diseases
  • Lead Product in Development :CB4211 for NASH and Obesity
  • Development Phase of Primary Product:Phase I
Simon Allen